Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis

ABSTRACT: Investigate changes in IL-23/Th17- and type I interferon-pathway biomarkers and gene responses, and measures of selectivity for TYK2 over Janus kinases (JAKs) 1–3, in patients with moderate to severe psoriasis receiving deucravacitinib.

PROVIDER: EGAS00001005875 | EGA |

REPOSITORIES: EGA